Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development

British Journal of Clinical Pharmacology

Volumn 77, Issue 6, 2014, Pages 947-957

  Van Meer, Leonie ^a   Moerland, Matthijs ^a   Cohen, Adam F ^a   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

biomarkers; early clinical trials; nephrotoxicity

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; KIDNEY INJURY MARKER 1; MEMBRANE PROTEIN; SPC 5001; UNCLASSIFIED DRUG; HAVCR1 PROTEIN, HUMAN; VIRUS RECEPTOR;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; CASE REPORT; DRUG DEVELOPMENT; DRUG EFFECTS; KIDNEY; MIDDLE AGED; URINE;

BIOLOGICAL MARKERS; DRUG DISCOVERY; EARLY DIAGNOSIS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, VIRUS;

EID: 84901359283     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12282     Document Type: Article

References (72)

1. van Poelgeest EP, Swart RM, Betjes MG, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, Burggraaf J,. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 2013; 62: 796-800.
2. Kola I, Landis J,. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3: 711-715.
3. Loghman-Adham M, Kiu Weber CI, Ciorciaro C, Mann J, Meier M,. Detection and management of nephrotoxicity during drug development. Expert Opin Drug Saf 2012; 11: 581-596.
4. McIlroy DR, Wagener G, Lee HT,. Biomarkers of acute kidney injury: an evolving domain. Anesthesiology 2010; 112: 998-1004.
5. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De ZD, Curhan GC, de Jong PE,. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421.
6. Traynor J, Mactier R, Geddes CC, Fox JG,. How to measure renal function in clinical practice. BMJ 2006; 333: 733-737.
7. Herget-Rosenthal S, Bokenkamp A, Hofmann W,. How to estimate GFR-serum creatinine, serum cystatin C or equations. Clin Biochem 2007; 40: 153-161.
8. Stevens PE, Levin A,. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825-830.
9. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, Kusek JW, Eggers P, Van LF, Greene T, Coresh J,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
12. Botev R, Mallie JP, Wetzels JF, Couchoud C, Schuck O, the clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin J Am Soc Nephrol 2011; 6: 937-950.
13. Stevens LA, Coresh J, Greene T, Levey AS,. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
14. Murty MS, Sharma UK, Pandey VB, Kankare SB,. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian J Nephrol 2013; 23: 180-183.
15. Vinken P, Starckx S, Barale-Thomas E, Looszova A, Sonee M, Goeminne N, Vermissen L, Buyens K, Lampo A,. Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicol Pathol 2012; 40: 1049-1062.
16. Sieber M, Hoffmann D, Adler M, Vaidya VS, Clement M, Bonventre JV, Zidek N, Rached E, Amberg A, Callanan JJ, Dekant W, Mally A,. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol Sci 2009; 109: 336-349.
17. Rahn KH, Heidenreich S, Bruckner D,. How to assess glomerular function and damage in humans. J Hypertens 1999; 17: 309-317.
18. Soares AA, Eyff TF, Campani RB, Ritter L, Camargo JL, Silveiro SP,. Glomerular filtration rate measurement and prediction equations. Clin Chem Lab Med 2009; 47: 1023-1032.
19. Prigent A,. [Measurement of renal function in clinical practice: principles and limitations]. J Radiol 2011; 92: 274-279.
20. Stevens LA, Levey AS,. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20: 2305-2313.
21. Thadhani R, Pascual M, Bonventre JV,. Acute renal failure. N Engl J Med 1996; 334: 1448-1460.
22. Blantz RC, Thomson SC, Peterson OW, Gabbai FB,. Physiologic adaptations of the tubuloglomerular feedback system. Kidney Int 1990; 38: 577-583.
23. Olson H, Betton G, Stritar J, Robinson D, the predictivity of the toxicity of pharmaceuticals in humans from animal data-an interim assessment. Toxicol Lett 1998; 102-103: 535-538.
24. Knight A,. Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern Lab Anim 2007; 35: 641-659.
25. Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, Mathieson PW, Monnens LA, van den Heuvel LP, Levtchenko EN,. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 2010; 339: 449-457.
26. Moghadasali R, Mutsaers HA, Azarnia M, Aghdami N, Baharvand H, Torensma R, Wilmer MJ, Masereeuw R,. Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity. Exp Toxicol Pathol 2013; 65: 595-600.
27. EMEA/FDA guideline on detection of drug-induced nephrotoxicity. 2009. Ref Type: Internet Communication.
28. Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, Hewitt P, Mally A,. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010; 277: 49-58.
29. Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, Wahl D, Legay F, Holder D, Erdos Z, Vlasakova K, Jin H, Yu Y, Muniappa N, Forest T, Clouse HK, Reynolds S, Bailey WJ, Thudium DT, Topper MJ, Skopek TR, Sina JF, Glaab WE, Vonderscher J, Maurer G, Chibout SD, Sistare FD, Gerhold DL,. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010; 28: 486-494.
30. Vassalos A, Young D, MacArthur K, Pollock J, Lyall F, Danton MH,. Cystatin C: influence of perfusion and myocardial injury on early (<24 h) renal function after pediatric cardiac surgery. Paediatr Anaesth 2011; 21: 1185-1191.
31. Tonomura Y, Tsuchiya N, Torii M, Uehara T,. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 2010; 273: 53-59.
32. Ding H, He Y, Li K, Yang J, Li X, Lu R, Gao W,. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007; 123: 227-234.
33. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, Mishra J, Devarajan P,. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2577-2584.
34. Yilmaz A, Sevketoglu E, Gedikbasi A, Karyagar S, Kiyak A, Mulazimoglu M, Aydogan G, Ozpacaci T, Hatipoglu S,. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol 2009; 24: 2387-2392.
35. Bani-Hani AH, Leslie JA, Asanuma H, Dinarello CA, Campbell MT, Meldrum DR, Zhang H, Hile K, Meldrum KK,. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. Kidney Int 2009; 76: 500-511.
36. Nozaki Y, Kinoshita K, Yano T, Asato K, Shiga T, Hino S, Niki K, Nagare Y, Kishimoto K, Shimazu H, Funauchi M, Matsumura I,. Signaling through the interleukin-18 receptor alpha attenuates inflammation in cisplatin-induced acute kidney injury. Kidney Int 2012; 82: 892-902.
37. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL,. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004; 43: 405-414.
38. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV,. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 28: 478-485.
39. Zhou Y, Vaidya VS, Brown RP, Zhang J, Rosenzweig BA, Thompson KL, Miller TJ, Bonventre JV, Goering PL,. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 2008; 101: 159-170.
40. Ouchi M, Suzuki T, Hashimoto M, Motoyama M, Ohara M, Suzuki K, Igari Y, Watanabe K, Nakano H, Urinary OK,. N-acetyl-beta-d-glucosaminidase levels are positively correlated with 2-hr plasma glucose levels during oral glucose tolerance testing in prediabetes. J Clin Lab Anal 2012; 26: 473-480.
41. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben A,. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50: 552-558.
42. Feinfeld DA, Fuh VL, Safirstein R,. Urinary glutathione-S-transferase in cisplatin nephrotoxicity in the rat. J Clin Chem.Clin Biochem 1986; 24: 529-532.
43. Feinfeld DA, Fleischner GM, Arias IM,. Urinary ligandin and glutathione-S-transferase in gentamicin-induced nephrotoxicity in the rat. Clin Sci (Lond) 1981; 61: 123-125.
44. Feinfeld DA, Bourgoignie JJ, Fleischner G, Goldstein EJ, Biempica L, Arias IM,. Ligandinuria in nephrotoxic acute tubular necrosis. Kidney Int 1977; 12: 387-392.
45. Harpur E, Ennulat D, Hoffman D, Betton G, Gautier JC, Riefke B, Bounous D, Schuster K, Beushausen S, Guffroy M, Shaw M, Lock E, Pettit S,. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol Sci 2011; 122: 235-252.
46. Swain A, Turton J, Scudamore C, Maguire D, Pereira I, Freitas S, Smyth R, Munday M, Stamp C, Gandhi M, Sondh S, Ashall H, Francis I, Woodfine J, Bowles J, York M,. Nephrotoxicity of hexachloro-1:3-butadiene in the male Hanover Wistar rat; correlation of minimal histopathological changes with biomarkers of renal injury. J Appl Toxicol 2012; 32: 417-428.
47. Bruning T, Sundberg AG, Birner G, Lammert M, Bolt HM, Appelkvist EL, Nilsson R, Dallner G,. Glutathione transferase alpha as a marker for tubular damage after trichloroethylene exposure. Arch Toxicol 1999; 73: 246-254.
48. Sundberg A, Appelkvist EL, Dallner G, Nilsson R,. Glutathione transferases in the urine: sensitive methods for detection of kidney damage induced by nephrotoxic agents in humans. Environ Health Perspect 1994; 102: (Suppl 3): 293-296.
49. Amin RP, Vickers AE, Sistare F, Thompson KL, Roman RJ, Lawton M, Kramer J, Hamadeh HK, Collins J, Grissom S, Bennett L, Tucker CJ, Wild S, Kind C, Oreffo V, Davis JW, Curtiss S, Naciff JM, Cunningham M, Tennant R, Stevens J, Car B, Bertram TA, Afshari CA,. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 2004; 112: 465-479.
50. Chiusolo A, Defazio R, Zanetti E, Mongillo M, Mori N, Cristofori P, Trevisan A,. Kidney injury molecule-1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: a tool for early screening of potential kidney toxicity. Toxicol Pathol 2010; 38: 338-345.
51. Rouse RL, Zhang J, Stewart SR, Rosenzweig BA, Espandiari P, Sadrieh NK,. Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney Int 2011; 79: 1186-1197.
52. Sasaki D, Yamada A, Umeno H, Kurihara H, Nakatsuji S, Fujihira S, Tsubota K, Ono M, Moriguchi A, Watanabe K, Seki J,. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 2011; 16: 553-566.
53. Prozialeck WC, Vaidya VS, Liu J, Waalkes MP, Edwards JR, Lamar PC, Bernard AM, Dumont X, Bonventre JV,. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int 2007; 72: 985-993.
54. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV,. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 2008; 1: 200-208.
55. Tsoukas CM, Bernard NF,. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 1994; 7: 14-28.
56. Bethea M, Forman DT,. Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci 1990; 20: 163-168.
57. Grundy JE,. Role of beta 2-microglobulin in cytomegalovirus infection. Scand J Rheumatol Suppl 1990; 87: 98-101.
58. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G,. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010; 28: 463-469.
59. Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, Tanuma J, Yazaki H, Ueda A, Kimura S, Oka S,. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2006; 22: 744-748.
60. Del PM, Romero S, Casado JL,. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev 2012; 14: 179-187.
61. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT,. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 2010; 56: 883-895.
62. Haring N, Mahr HS, Mundle M, Strohal R, Lhotta K,. Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary beta2-microglobulin. Br J Dermatol 2011; 164: 648-651.
63. Rosenberg ME, Silkensen J,. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633-645.
64. Dvergsten J, Manivel JC, Correa-Rotter R, Rosenberg ME,. Expression of clusterin in human renal diseases. Kidney Int 1994; 45: 828-835.
65. Madsen J, Nielsen O, Tornoe I, Thim L, Holmskov U,. Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem 2007; 55: 505-513.
66. Chinery R, Poulsom R, Elia G, Hanby AM, Wright NA,. Expression and purification of a trefoil peptide motif in a beta-galactosidase fusion protein and its use to search for trefoil-binding sites. Eur J Biochem 1993; 212: 557-563.
67. Kinoshita K, Taupin DR, Itoh H, Podolsky DK,. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000; 20: 4680-4690.
68. Debata PR, Panda H, Supakar PC,. Altered expression of trefoil factor 3 and cathepsin L gene in rat kidney during aging. Biogerontology 2007; 8: 25-30.
69. Yu Y, Jin H, Holder D, Ozer JS, Villarreal S, Shughrue P, Shi S, Figueroa DJ, Clouse H, Su M, Muniappa N, Troth SP, Bailey W, Seng J, Aslamkhan AG, Thudium D, Sistare FD, Gerhold DL,. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 2010; 28: 470-477.
70. Astor BC, Kottgen A, Hwang SJ, Bhavsar N, Fox CS, Coresh J,. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol 2011; 34: 291-297.
71. Prozialeck WC, Edwards JR,. Early biomarkers of cadmium exposure and nephrotoxicity. Biometals 2010; 23: 793-809.
72. Fujita H, Narita T, Morii T, Shimotomai T, Yoshioka N, Kakei M, Ito S,. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren Fail 2002; 24: 69-75.